耳鼻咽喉科・頭頸部外科92巻9号

2020年08月発行

特集 唾液腺腫瘍の診療最前線

《治療》

薬物療法

著者： 多田雄一郎¹

所属機関： ¹国際医療福祉大学三田病院頭頸部腫瘍センター

ページ範囲：P.730 - P.738

文献概要

POINT

●再発転移唾液腺癌では各腫瘍型の生物学的特徴に応じて薬物治療の適応を検討する。

●比較試験を経たエビデンスのある薬物治療はない。

●本邦で白金製剤とタキサン系抗癌剤の併用療法の有用性が報告されており，有力な選択肢となる。

●NCCNガイドライン2020年版では，唾液腺導管癌には抗アンドロゲン療法や抗HER2療法，分泌癌には抗NTRK療法，腺様嚢胞癌にはレンバチニブの投与が呈示された。

参考文献

1）NCCN Clinical Practice Guidelines in Oncology, Head and Neck Cancers. Version 1.2020：https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf（accessed 2020/03/31）

2）日本頭頸部癌学会（編）：頭頸部癌診療ガイドライン2018年版．金原出版，東京，2017，pp70-73（唾液腺癌（耳下腺癌））

3）Lewis AG, et al：Diagnosis and management of malignant salivary gland tumors of the parotid gland. Otolaryngol Clin North Am 49：343-380, 2016

4）Alfieri S, et al：Systemic therapy in metastatic salivary gland carcinomas：A pathology-driven paradigm? Oral Oncol 66：58-63, 2017

5）日本臨床腫瘍学会（編）：頭頸部がん薬物療法ガイダンス 第2版．金原出版，東京，2018

6）Mimica X, et al：Distant metastasis of salivary gland cancer：Incidence, management, and outcomes. Cancer 126：2153-2162, 2020

7）Fushimi C, et al：A prospective phase Ⅱ study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol 29：979-984, 2018

8）Locati LD, et al：Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers. Head Neck 38：724-731, 2016

9）Boon E, et al：Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma：A nationwide case series of 35 patients in The Netherlands. Head Neck 40：605-613, 2018

10）Viscuse PV, et al：First line androgen deprivation therapy vs. chemotherapy for patients with androgen receptor positive recurrent or metastatic salivary gland carcinoma-A retrospective study. Front Oncol 9：701, 2019

11）Takahashi H, et al：Phase Ⅱ trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol 37：125-134, 2019

12）Kurzrock R, et al：Targeted therapy for advanced salivary gland carcinoma based on molecular profiling：results from MyPathway, a phase Ⅱa multiple basket study. Ann Oncol 31：412-421, 2020

13）Li BT, et al：Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers（SGCs）：Results from a phase Ⅱ basket trial. J Clin Oncol 37（Suppl）：abstr 6001, 2019

14）Jhaveri KL, et al：Ado-trastuzumab emtansine（T-DM1）in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction（GEJ）adenocarcinomas：results from the NCI-MATCH trial（EAY131）subprotocol Q. Ann Oncol 30：1821-1830, 2019

15）Tsurutani J, et al：Targeting HER2 with trastuzumab deruxtecan：a dose-expansion, phase Ⅰ study in multiple advanced solid tumors. Cancer Discov 10：668-701, 2020

16）Hong DS, et al：Larotrectinib in patients with TRK fusion-positive solid tumours：a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol 21：531-540, 2020

17）Doebele RC, et al：Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours：integrated analysis of three phase 1-2 trials. Lancet Oncol 21：271-282, 2020

18）Tchekmedyian V, et al：Phase Ⅱ study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol 37：1529-1537, 2019

19）Locati LD, et al：Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib：Activity and quality of life. Cancer 26：1888-1894, 2020

20）Ferrarotto R, et al：ACCURACY a phase（P）Ⅱ trial of AL101, a pan-Notch inhibitor, in recurrent/metastatic（R/M）adenoid cystic carcinoma（Acc）patients（pts）with Notch activating mutations（Notchactmut）：Preliminary safety and efficacy data. Ann Oncol 30（suppl_5）：v465-v466, 2019

21）Nagao T, et al：Salivary duct carcinoma. In：WHO classification of head and neck tumours 4th ed, El-Naggar AK, et al（eds）. IARC, Lyon, 2017, pp173-174

22）Otsuka K, et al：Clinical outcomes and prognostic factors for salivary duct carcinoma：A multi-institutional analysis of 141 patients. Ann Surg Oncol 23：2038-2045, 2016

23）Masubuchi T, et al：Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma. Int J Clin Oncol 20：35-44, 2015

24）Takase S, et al：Biomarker immunoprofile in salivary duct carcinomas：clinicopathological and prognostic implications with evaluation of the revised classification. Oncotarget 8：59023-59035, 2017

25）Boon E, et al：A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands. Int J Cancer 143：758-766, 2018

26）Okada T, et al：Carboplatin and docetaxel in patients with salivary gland carcinoma：a retrospective study. In Vivo 33：843-853, 2019

27）Ho AL, et al：Alliance A091404：A phase Ⅱ study of enzalutamide（NSC# 766085）for patients with androgen receptor-positive salivary cancers. J Clin Oncol 37（Suppl）abstr 6020, 2019

28）van der Hulst RW, et al：Partial remission of parotid gland carcinoma after goserelin. Lancet 344：817, 1994

29）Locati LD, et al：Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy. Cancer Biol Ther 15：678-682, 2014

30）Urban D, et al：Abiraterone in metastatic salivary duct carcinoma. J Natl Compr Canc Netw 13：288-290, 2015

31）Dalgleish AG, et al：The successful treatment of metastatic androgen receptor-positive tumours of parotid origin with androgen receptor blockade and immunotherapy. Eur J Cancer 113：14-18, 2019

32）黒田裕行・他：抗アンドロゲン療法と化学療法が奏効した進行唾液腺導管癌の1例．癌と化療38：627-630，2011

33）Yajima Y, et al：Anti-androgen therapy for the patients with recurrent and/or metastatic salivary duct carcinoma expressing androgen receptors：a retrospective study. Ann Oncol 23：Abs 1706P, 2012

34）Yamamoto N, et al：Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy. Am J Otolaryngol 35：731-735, 2014

35）菅野真史・他：アンドロゲンレセプター陽性進行唾液腺導管癌に対する抗アンドロゲン療法の臨床検討．頭頸部癌43：49-55，2017

36）大江祐一郎・他：唾液腺導管癌局所再発・多発骨転移に対しビカルタミドが奏功した1例．頭頸部癌43：478-482，2017

37）Wasano K, et al：Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma：A case report. Rare Tumors 10：2036361318798867, 2018

38）Haddad R, et al：Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase Ⅱ study. Oral Oncol 39：724-727, 2003

39）Fiedler W, et al：Phase Ⅰ study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours. ESMO Open 3：e000381, 2018

40）蓮尾麻里・他：HER-2蛋白を発現したSalivary Duct Carcinomaにおけるトラスツズマブ使用の検討．頭頸部癌32：68-71，2006

41）Kadowaki S, et al：Complete response to trastuzumab-based chemotherapy in a patient with human epidermal growth factor receptor-2-positive metastatic salivary duct carcinoma ex pleomorphic adenoma. Case Rep Oncol 6：450-455, 2013

42）井口福一郎・他：トラスツズマブによる分子標的治療が著効した転移性唾液腺導管癌例．日耳鼻117：1108-1114，2014

43）青井二郎・他：トラスツズマブが著効した副耳下腺原発の唾液腺導管癌多発性骨転移例．耳鼻108：221-227，2015

44）小山哲史・他：唾液腺導管癌に対するトラスツズマブの使用経験．耳鼻108：483-488，2015

45）籔内 咲・他：ドセタキセルとトラスツズマブを長期間投与した顎下腺原発唾液腺導管癌例．耳鼻110：693-699，2017

46）Licitra L, et al：Cisplatin in advanced salivary gland carcinoma. A phase Ⅱ study of 25 patients. Cancer 68：1874-1877, 1991

47）Licitra L, et al：Cisplatin, doxorubicin and cyclophosphamide in advanced salivary gland carcinoma. A phase Ⅱ trial of 22 patients. Ann Oncol 7：640-642, 1996

48）Gilbert J, et al：Phase Ⅱ trial of taxol in salivary gland malignancies（E1394）：a trial of the Eastern Cooperative Oncology Group. Head Neck 28：197-204, 2006

49）Laurie SA, et al：A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer：a trial of the NCIC Clinical Trials Group. Cancer 116：362-368, 2010

50）Debaere D, et al：Cyclophosphamide, doxorubicin, and cisplatin in advanced salivary gland cancer. B-ENT 7：1-6, 2011

51）Airoldi M, et al：Cisplatin＋vinorelbine treatment of recurrent or metastatic salivary gland malignancies（RMSGM）：a final report on 60 cases. Am J Clin Oncol 40：86-90, 2017

52）Rodriguez CP, et al：Phase Ⅱ trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies. Head Neck 40：584-589, 2018

53）Nakano K, et al：Combination chemotherapy of carboplatin and paclitaxel for advanced/metastatic salivary gland carcinoma patients：differences in responses by different pathological diagnoses. Acta Otolaryngol 136：948-951, 2016

54）今村義宣：再発・転移の頭頸部非扁平上皮癌にDTX＋CDDP併用療法は有用か？　頭頸部がんの最適化医療—根治とQOLの両立を目指して，丹生健一．神戸大学大学院医学研究科外科系講座耳鼻咽喉科頭頸部外科学分野，2019，pp216-221

55）Solomon JP, et al：NTRK fusion detection across multiple assays and 33,997 cases：diagnostic implications and pitfalls. Mod Pathol 33：38-46, 2020

56）Ho AS, et al：Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. J Clin Invest 129：4276-4289, 2019

57）Hyman DM, et al：Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373：726-736, 2015

58）Klempner SJ, et al：Identification of BRAF kinase domain duplications across multiple tumor types and response to RAF inhibitor therapy. JAMA Oncol 2：272-274, 2016

59）Wang K, et al：Profiling of 149 salivary duct carcinomas, carcinoma ex pleomorphic adenomas, and adenocarcinomas, not otherwise specified reveals actionable genomic alterations. Clin Cancer Res 22：6061-6068, 2016

60）Lin VTG, et al：First-line treatment of widely metastatic BRAF-mutated salivary duct carcinoma with combined BRAF and MEK inhibition. J Natl Compr Canc Netw 16：1166-1170, 2018

61）Linxweiler M, et al：The immune microenvironment and neoantigen landscape of aggressive salivary gland carcinomas differ by subtype. Clin Cancer Res, 2020　doi：10.1158/1078-0432.CCR-19-3758［Epub ahead of print］

62）Cohen RB, et al：Pembrolizumab for the treatment of advanced salivary gland carcinoma：findings of the phase 1b KEYNOTE-028 study. Am J Clin Oncol 41：1083-1088, 2018

63）Rodriguez CP, et al：A phase Ⅱ trial of pembrolizumab and vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer. Clin Cancer Res 26：837-845, 2020

64）Hori R, et al：Real-world outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic head and neck carcinoma. Cancers（Basel） 11：1317, 2019

65）Kokkali S, et al：Nivolumab in patients with rare head and neck carcinomas：A single center's experience. Oral Oncol 101：104359, 2020